Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Tubilux Pharma Spa
WARNING LETTER
•Tubilux Pharma Spa•December 9, 2016

Tubilux Pharma Spa – FDA Warning Letter, Dec 9, 2016

Record Details

The FDA issued a Warning Letter to Tubilux Pharma S.p.A. following an inspection from December 1-9, 2016, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated.

Violations include: 1. **Equipment Design and Airflow (21 CFR 211.63):** Turbulent airflow was observed in aseptic processing line smoke studies (September 2015, December 2016), posing a contamination hazard. Unidirectional airflow was not established where caps are applied. Dynamic smoke studies showed turbulent airflow during manual loading of sterile components, and operators performed manually intensive aseptic activities with significant interventions. The FDA requires identification of all contamination hazards, a formal risk assessment of process, equipment, and facility hazards, and a comprehensive CAPA plan.

2. **Laboratory Controls and Particulate Testing (21 CFR 211.160(b)):** The firm failed to test ophthalmic products for particulates prior to release, despite observing high particle count alarms. The FDA requires an implementation plan for particulate matter testing, revised drug product specifications, and a written procedure for in-process inspection of visible particles.

Additional CGMP deficiencies noted include: * **Sterility Testing:** The use of a (b)(4) cycle for sterility test samples may compromise validity by killing or injuring organisms. A CAPA is required to remediate this. *

Company
Tubilux Pharma Spa
Inspection date
December 9, 2016
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas J. Cosgrove
View Company Profile

ID · c8ae5092-6c27-4868-85f5-19a87dfb6509

Violation Codes7
21 CFR 21021 CFR 21121 CFR 211.6321 CFR 211.160(b)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Tubilux Pharma Spa
  • 483 - 2019-12-02December 2, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Tubilux Pharma Spa
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.